JAMA Network Home
Sign In
Editor's Pick Original Investigation

First- and Second-Year Outcomes After Nirsevimab Immunization

JAMA Pediatrics 10.1001/jamapediatrics.2026.3384

August 10, 2026 at 11:00 AM EDT

Read the full article

This study found that nirsevimab was associated with a substantial reduction in RSV-LRTI–related hospitalizations during the first year across both the 2023-2024 and 2024-2025 seasons. It was not associated with reduced hospitalizations due to non-RSV infections or asthma, nor during the second year of follow-up.

Corresponding Author: Amélie Gabet, PhD, Department of Epidemiology and Health Product (EPI-PHARE), French National Agency for Medicines and Health Products Safety and French National Health Insurance (ANSM), 143 Boulevard Anatole France, 93285 Saint-Denis Cedex, France (amelie.gabet@ansm.sante.fr).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2026.3384?utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_term=081026

Copy to clipboard

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.

Editor's Picks